GlaxoSmithKline announced on October 9th that it has reached agreements with 10 plaintiff companies, representing a total of 93% (approximately 80000 cases) of the pending lawsuit against GlaxoSmithKline's heartburn drug Zantac in state courts in the United States. According to these agreements, GlaxoSmithKline will pay a total of up to $2.2 billion to resolve these cases. The agreement is expected to be fully implemented by the end of the first half of 2025, and the terms of the agreement will be kept confidential. GlaxoSmithKline did not acknowledge any responsibility in the principle agreement of the settlement.